Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q3 2023 · 10-Q
Revenue$20.00K$20.00K−60.0% vs Q3 2022 Net Income-$4.91M-$4.91MN/M vs Q3 2022 EPS Diluted-$15.25-$15.25N/M vs Q3 2022 Operating Income-$5,834,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,113,000N/M Margins · derivedOperating margin-29170.0%−19586.0 pt vs Q3 2022
Net margin-24560.0%−15042.0 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end